LFF571 is a novel semi-synthetic analog of the thiopeptide natural product GE2270 A and a potent inhibitor of Gram-positive aerobic and anaerobic bacteria. The parent compound is a translational inhibitor that binds elongation factor Tu (EF-Tu) and blocks its function. Here we report an analogous mechanism of action for LFF571 against Clostridium difficile. In exponentially growing cultures, LFF571 inhibited protein synthesis with an IC50 of 0.06 µg/ml. We also determined the frequency and mechanism of reduced susceptibility to the compound in vitro. Single-step, spontaneous mutants of C. difficile were selected on super-inhibitory concentrations of LFF571 at a frequency of <4.5 x 10-11 to 1.2 x 10-9. No C. difficile mutants with loss of LF...
The US Centers for Disease Control and Prevention (CDC) lists Clostridioides difficile as an urgent ...
Antibiotic resistance is a worldwide challenge. A potential approach to block resistance is to simul...
Antibiotics are considered to be the first line of treatment for mild to moderately severe Clostridi...
LFF571 is a novel semi-synthetic thiopeptide antibacterial that is undergoing investigation for safe...
The in vitro activities of LFF571, a novel analog of GE2270A that inhibits bacterial growth by bindi...
Aminothiazole derivatives of GE2270 A are novel, semi-synthetic analogs of the thiopeptide class of ...
Recently, we identified aminothiazole derivatives of GE2270 A. These novel semisynthetic congeners, ...
Clostridium difficile is a Gram positive, spore-forming, anaerobic bacterium which infects the lumen...
Resistance to antibiotics has increased and is still growing so that almost every human pathogen has...
Clostridioides difficile, formerly in the genus Clostridium, is a Gram positive obligatory anaerobic...
Clostridium difficile is the leading cause of hospital-acquired infectious diarrhea. LFF571 is a nov...
Probiotics may offer an attractive alternative for standard antibiotic therapy to treat Clostridium ...
CB-183,315 is a novel lipopeptide antibiotic structurally related to daptomycin currently in phase 3...
Background: C.difficile infection (CDI) is now established as a major healthcare issue. However, the...
Master of ScienceDepartment of Plant PathologyRevathi GovindClostridium difficile, a gram-positive, ...
The US Centers for Disease Control and Prevention (CDC) lists Clostridioides difficile as an urgent ...
Antibiotic resistance is a worldwide challenge. A potential approach to block resistance is to simul...
Antibiotics are considered to be the first line of treatment for mild to moderately severe Clostridi...
LFF571 is a novel semi-synthetic thiopeptide antibacterial that is undergoing investigation for safe...
The in vitro activities of LFF571, a novel analog of GE2270A that inhibits bacterial growth by bindi...
Aminothiazole derivatives of GE2270 A are novel, semi-synthetic analogs of the thiopeptide class of ...
Recently, we identified aminothiazole derivatives of GE2270 A. These novel semisynthetic congeners, ...
Clostridium difficile is a Gram positive, spore-forming, anaerobic bacterium which infects the lumen...
Resistance to antibiotics has increased and is still growing so that almost every human pathogen has...
Clostridioides difficile, formerly in the genus Clostridium, is a Gram positive obligatory anaerobic...
Clostridium difficile is the leading cause of hospital-acquired infectious diarrhea. LFF571 is a nov...
Probiotics may offer an attractive alternative for standard antibiotic therapy to treat Clostridium ...
CB-183,315 is a novel lipopeptide antibiotic structurally related to daptomycin currently in phase 3...
Background: C.difficile infection (CDI) is now established as a major healthcare issue. However, the...
Master of ScienceDepartment of Plant PathologyRevathi GovindClostridium difficile, a gram-positive, ...
The US Centers for Disease Control and Prevention (CDC) lists Clostridioides difficile as an urgent ...
Antibiotic resistance is a worldwide challenge. A potential approach to block resistance is to simul...
Antibiotics are considered to be the first line of treatment for mild to moderately severe Clostridi...